Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG MIX 70 30 PENFILL versus NOVOLOG PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG MIX 70 30 PENFILL versus NOVOLOG PENFILL.
NOVOLOG MIX 70/30 PENFILL vs NOVOLOG PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Novolog Mix 70/30 is a biphasic insulin analog suspension containing 70% insulin aspart protamine (intermediate-acting) and 30% insulin aspart (rapid-acting). Insulin aspart binds to the insulin receptor (IR) on target cells (muscle, adipose, liver), activating tyrosine kinase signaling, which promotes glucose uptake via GLUT4 translocation, inhibits hepatic gluconeogenesis, and stimulates glycogen synthesis and lipogenesis.
Insulin aspart is a rapid-acting recombinant human insulin analog. It lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, promoting glucose uptake, and inhibiting hepatic glucose production via glycogenolysis and gluconeogenesis.
Subcutaneous injection, typically 0.5–1 unit/kg/day divided into two doses: two-thirds in the morning and one-third in the evening, adjusted based on blood glucose levels.
Subcutaneous injection: 0.5-1 unit/kg/day divided into multiple doses (e.g., basal-bolus regimen). Individualized based on glucose monitoring.
None Documented
None Documented
Biphasic: first phase (distribution) 0.5-1 h; terminal (elimination) 5-7 h (insulin aspart component). Clinical context: covers prandial and basal needs with twice-daily dosing.
~5-7 minutes (free insulin aspart); clinical effect duration correlates with SC absorption half-life ~1-2 hours
Renal: 100% (protamine and insulin are metabolized and excreted via kidneys; no unchanged drug excreted in urine). Biliary/fecal: negligible.
Renal: 60-80% as metabolites; unchanged drug excreted minimally. Fecal: <10%
Category C
Category C
Insulin Analog
Insulin Analog